Non-Psychoactive Cannabinoid Pain Relief: CBD, CBG, and Emerging Options

Executive Summary

Non-psychoactive cannabinoids represent a breakthrough class of pain relief compounds derived from cannabis that deliver therapeutic benefits without intoxication. Recent research published in June 2026 identified specific cannabis compounds capable of relieving pain through novel mechanisms that bypass the CB1 receptors responsible for the "high" associated with THC. This discovery addresses one of the most significant barriers to medical cannabis adoption: the separation of analgesic effects from cognitive impairment. For the estimated 50 million American adults living with chronic pain, non-psychoactive cannabinoids offer a potential alternative to opioids and traditional NSAIDs. The compounds under investigation include CBD, CBG, CBDA, THCV, and newly isolated minor cannabinoids that interact with pain pathways through the endocannabinoid system, vanilloid receptors, and inflammatory cascades. As federal rescheduling of cannabis progresses and the FDA evaluates cannabinoid-based therapeutics, these non-intoxicating compounds are positioned to reshape pain management protocols across hospitals, clinics, and palliative care settings nationwide.

Why This Matters

The development of non-psychoactive cannabinoid pain relief directly impacts 100+ million patients, a $20 billion analgesic market, and the ongoing opioid epidemic that claims 80,000 American lives annually. The stakeholder landscape spans multiple sectors. Chronic pain patients—including the 20.9% of U.S. adults with chronic pain according to CDC data—face limited options between addictive opioids, liver-toxic acetaminophen, and gastrointestinal-damaging NSAIDs. Non-psychoactive cannabinoids offer a fourth pathway with distinct safety profiles. For elderly patients, veterans, and individuals in safety-sensitive occupations, intoxication-free pain relief removes the primary obstacle to cannabinoid therapy adoption. Healthcare systems stand to reduce opioid prescription volumes, which reached 142.2 million prescriptions in 2020 despite declining trends. Workers' compensation insurers in states like California, New York, and Ohio are already evaluating CBD and CBG formulations as alternatives to Schedule II narcotics, seeking to lower addiction liability and long-term disability costs. The pharmaceutical industry faces both disruption and opportunity. Major drugmakers including GW Pharmaceuticals (now Jazz Pharmaceuticals), Cara Therapeutics, and Artelo Biosciences have invested over $400 million in cannabinoid pain research since 2018. The global cannabinoid pharmaceuticals market is projected to reach $9.7 billion by 2028, with non-psychoactive formulations capturing the majority share due to regulatory advantages and prescriber acceptance. Employers and insurers are watching closely. Workplace drug testing policies, aviation regulations under 14 CFR Part 120, and Department of Transportation rules under 49 CFR Part 40 currently prohibit cannabis use regardless of medical status. Non-psychoactive cannabinoids that produce negative THC screens could enable millions of commercial drivers, pilots, and federal employees to access cannabinoid therapy without career consequences.

Background and History

The scientific pursuit of non-psychoactive cannabis compounds began in 1940 when Roger Adams first isolated CBD, though its therapeutic potential remained obscure for decades.

1940-1963: Early Cannabinoid Isolation

Roger Adams at the University of Illinois isolated cannabidiol in 1940 from Minnesota wild hemp, but lacked the analytical tools to determine its precise structure or pharmacology. The compound remained a laboratory curiosity while cannabis prohibition under the Marihuana Tax Act of 1937 restricted research access. In 1963, Israeli chemist Raphael Mechoulam at Hebrew University elucidated CBD's exact molecular structure, followed by THC's structure in 1964. Mechoulam's work established that cannabis contained distinct compounds with different pharmacological profiles—a finding that would take 30 years to influence medical practice.

1988-1992: Endocannabinoid System Discovery

The 1988 discovery of the CB1 receptor by Allyn Howlett and William Devane at St. Louis University School of Medicine revealed why THC produced intoxication: CB1 receptors concentrated in brain regions governing cognition, memory, and motor control. The 1993 identification of the CB2 receptor, primarily expressed in immune tissues and peripheral nervous system, suggested therapeutic targets divorced from psychoactivity. This receptor bifurcation provided the biological rationale for non-psychoactive cannabinoid development. The 1992 discovery of anandamide, the body's endogenous cannabinoid, by Mechoulam's team demonstrated that humans possessed an entire signaling system modulating pain, inflammation, and homeostasis. This endocannabinoid system became the mechanistic foundation for cannabinoid therapeutics.

1996-2003: Medical Cannabis Legalization and CBD Emergence

California's Proposition 215 in 1996 launched state-level medical cannabis programs, but early formulations emphasized high-THC products for appetite stimulation and nausea. CBD remained largely ignored until 2003, when the U.S. government received Patent No. 6,630,507 titled "Cannabinoids as antioxidants and neuroprotectants," assigned to the Department of Health and Human Services. The patent explicitly covered CBD and other non-psychoactive cannabinoids for treating oxidative stress and neurological conditions—a federal acknowledgment of therapeutic potential even as the DEA maintained cannabis as Schedule I.

2008-2013: Preclinical Pain Research Acceleration

Between 2008 and 2013, over 40 peer-reviewed studies documented CBD's analgesic effects in animal models. A 2008 review in Therapeutics and Clinical Risk Management by Russo summarized evidence for CBD in treating neuropathic pain, multiple sclerosis spasticity, and cancer pain. Researchers identified multiple mechanisms: TRPV1 vanilloid receptor activation, adenosine receptor enhancement, glycine receptor modulation, and 5-HT1A serotonin receptor agonism. Unlike opioids acting on mu-opioid receptors or NSAIDs inhibiting COX enzymes, CBD engaged pain pathways through at least six distinct receptor systems.

2013-2018: Epidiolex Development and FDA Approval

The 2013 CNN documentary featuring Charlotte Figi, a child with Dravet syndrome whose seizures responded to high-CBD cannabis oil, catalyzed public and scientific interest. GW Pharmaceuticals accelerated clinical trials of Epidiolex, a purified CBD oral solution. On June 25, 2018, the FDA approved Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome—the first cannabis-derived drug to receive federal approval. The DEA subsequently rescheduled FDA-approved CBD formulations to Schedule V under 21 U.S.C. § 812, creating a legal paradox where pharmaceutical CBD was Schedule V but botanical CBD remained Schedule I. The approval process generated critical safety data: clinical trials involving over 500 patients established that CBD doses up to 20 mg/kg/day produced no intoxication, minimal abuse potential, and manageable side effects (diarrhea, somnolence, elevated liver enzymes). This data became the foundation for pain-focused CBD research.

2018-2024: Minor Cannabinoid Exploration

The 2018 Farm Bill's legalization of hemp (cannabis with ≤0.3% THC) under 7 U.S.C. § 1639o unleashed commercial and academic interest in minor cannabinoids. Researchers identified over 120 distinct cannabinoids, many with potential analgesic properties: - **CBG (cannabigerol)**: Studies at Dalhousie University in 2021 showed CBG reduced inflammatory pain in mice through alpha-2 adrenergic receptor activation - **CBDA (cannabidiolic acid)**: 2022 research at the University of Guelph demonstrated CBDA's superior bioavailability and anti-inflammatory effects compared to decarboxylated CBD - **THCV (tetrahydrocannabivarin)**: A 2020 British Journal of Pharmacology study found THCV acted as a CB1 antagonist, blocking THC's psychoactivity while reducing inflammatory pain - **CBC (cannabichromene)**: 2019 research documented interaction with TRPA1 channels involved in pain sensation By 2024, over 15 clinical trials were registered at ClinicalTrials.gov investigating non-psychoactive cannabinoids for chronic pain conditions.

2024-2026: Breakthrough Discoveries

The June 2026 announcement of a newly characterized cannabis compound with potent analgesic effects and zero psychoactivity represents the culmination of this 86-year research arc. While the specific compound awaits peer review and publication, the discovery follows established patterns: isolation of minor cannabinoids, receptor binding assays identifying non-CB1 mechanisms, behavioral testing in rodent pain models, and confirmation of absence of intoxication markers. This finding arrives as the DEA's proposed rescheduling of cannabis to Schedule III under the 2024 NPRM creates a more permissive research environment.

Key Players

Federal Agencies

The **Drug Enforcement Administration** controls cannabis research access through the single-source NIDA supply monopoly, though the agency's May 2024 proposal to reschedule cannabis to Schedule III under 21 CFR Part 1308 would expand research opportunities. The **Food and Drug Administration** evaluates cannabinoid therapeutics under the same standards as conventional drugs, having approved Epidiolex, Marinol, Syndros, and Cesamet. The FDA's Botanical Drug Development guidance issued in 2016 provides the regulatory pathway for whole-plant cannabinoid formulations. The **National Institutes of Health** allocated $196 million to cannabinoid research in fiscal year 2023, with the National Institute on Drug Abuse, National Center for Complementary and Integrative Health, and National Cancer Institute funding pain-focused studies. The **National Institute on Drug Abuse** operates the sole DEA-licensed cannabis cultivation facility at the University of Mississippi, though the DEA approved additional cultivators in 2021.

Academic Research Centers

**University of California San Diego's Center for Medicinal Cannabis Research**, established by California Senate Bill 847 in 1999, has published over 30 peer-reviewed studies on cannabinoid analgesia. Director Dr. Igor Grant's team conducted the first FDA-approved trials of smoked cannabis for neuropathic pain. **Johns Hopkins University School of Medicine** operates a dedicated cannabinoid research program that published 2022 findings on CBD's effects in chronic pain patients, documenting 30% pain reduction without cognitive impairment. **Hebrew University of Jerusalem** remains the global leader in cannabinoid chemistry, where Raphael Mechoulam continued research until his death in 2023. His protégés isolated over 40 minor cannabinoids between 2015 and 2025. **Dalhousie University** in Nova Scotia leads CBG research, with 2021 publications establishing its mechanism in inflammatory bowel disease and pain models.

Pharmaceutical Companies

**Jazz Pharmaceuticals** (which acquired GW Pharmaceuticals for $7.2 billion in 2021) holds the dominant position with Epidiolex and an extensive cannabinoid patent portfolio covering formulations, dosing regimens, and combination therapies. The company initiated Phase II trials in 2025 for a CBD-based chronic pain indication. **Cara Therapeutics** focuses on kappa-opioid receptor agonists but expanded into cannabinoid research in 2023, licensing CBG formulations from the University of Guelph. **Artelo Biosciences** develops synthetic cannabinoid analogs, including ART27.13, a fatty acid binding protein inhibitor that enhances endocannabinoid signaling without exogenous cannabinoid administration. **Canopy Growth Corporation**, through its subsidiary C3 Cannabinoid Compound Company, invested $150 million in minor cannabinoid isolation and clinical development between 2020 and 2024. **Curaleaf Holdings** operates the largest vertically integrated cannabis company in the U.S., with research partnerships at the University of Maryland and Rutgers University focused on standardized CBD and CBG formulations for pain.

Patient Advocacy Organizations

**Americans for Safe Access**, founded in 2002, advocates for medical cannabis patient rights and funded the 2019 "Cannabinoids in Pain Management" white paper documenting patient experiences with non-psychoactive formulations. **U.S. Pain Foundation** represents 50 million chronic pain patients and issued 2023 policy recommendations supporting access to non-intoxicating cannabinoid therapies as opioid alternatives. **Veterans Cannabis Project** focuses on the 2.5 million veterans with chronic pain, lobbying for VA physician authorization to recommend cannabinoids and funding research at the University of California Los Angeles on CBD for PTSD-associated pain.

Legal and Regulatory Framework

Non-psychoactive cannabinoids occupy a complex legal space spanning the Controlled Substances Act, the Farm Bill, FDA drug approval pathways, and state medical cannabis programs. The **Controlled Substances Act of 1970** (21 U.S.C. § 801 et seq.) placed cannabis in Schedule I, defined as having no accepted medical use and high abuse potential. This classification applied to all cannabis-derived compounds except synthetic THC (dronabinol), which the DEA scheduled separately. The CSA's definition of "marihuana" at 21 U.S.C. § 802(16) excluded "mature stalks" and "sterilized seed," creating ambiguity about cannabinoid extracts. The **Agricultural Improvement Act of 2018** (Farm Bill) amended the CSA to exclude "hemp"—cannabis with ≤0.3% delta-9 THC—from the definition of marihuana under 7 U.S.C. § 1639o. This legalized hemp-derived CBD and other cannabinoids at the federal level, provided THC content remained below the threshold. The U.S. Department of Agriculture regulates hemp cultivation under 7 CFR Part 990, requiring state and tribal plans for THC testing and remediation. However, the **Food, Drug, and Cosmetic Act** at 21 U.S.C. § 331(ll) prohibits adding CBD to food or marketing it as a dietary supplement because it is the active ingredient in FDA-approved drug Epidiolex. The FDA issued warning letters to 22 CBD companies between 2019 and 2024 for unapproved drug claims. The agency maintains that cannabinoids require New Drug Applications unless marketed as hemp products with no therapeutic claims. The **DEA's proposed rescheduling** published in the Federal Register on May 16, 2024 (Docket No. DEA-407), would move cannabis to Schedule III under 21 CFR § 1308.13, alongside ketamine and anabolic steroids. Schedule III status would: - Permit state-licensed cannabis businesses to deduct ordinary business expenses under 26 U.S.C. § 280E - Expand research access by reducing DEA licensing requirements - Allow physicians to prescribe (rather than merely recommend) cannabis in medical states - Maintain federal prohibition on recreational use and interstate commerce The rescheduling does not resolve FDA approval requirements—cannabinoid products would still require NDAs for therapeutic claims regardless of schedule. At the state level, 38 states and the District of Columbia have legalized medical cannabis as of June 2026, with varying provisions for non-psychoactive cannabinoids. **New York's Cannabis Law** (Article 4) specifically authorizes low-THC, high-CBD products for registered patients. **Texas's Compassionate Use Act** (Health and Safety Code § 169.001) restricts medical cannabis to products with ≤1% THC and ≥10% CBD, effectively mandating non-psychoactive formulations. **Virginia** permits CBD and CBG products derived from hemp without medical registration under Code of Virginia § 3.2-4112.

State-by-State Breakdown

California

California's medical cannabis program under the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) permits physicians to recommend any cannabis product, including non-psychoactive formulations, for any condition where cannabis provides relief. Possession limits reach 8 ounces of dried flower or equivalent concentrates for medical patients. The state's Bureau of Cannabis Control requires testing for cannabinoid content, allowing patients to select high-CBD, low-THC products. Hemp-derived CBD products with ≤0.3% THC are legal without medical registration. Key date: Proposition 215 passed November 5, 1996.

New York

New York's Office of Cannabis Management oversees medical cannabis under Cannabis Law Article 4, enacted March 31, 2021. The program includes a specific "low-THC cannabis" category for products with ≤3% THC and ≥1% CBD, designed for patients seeking non-psychoactive relief. Registered patients may possess up to a 60-day supply as determined by their certifying practitioner. Hemp-derived CBD is legal statewide. The state funds research at Columbia University and Mount Sinai on CBD for chronic pain. Key date: Medical program launched January 2016.

Ohio

Ohio's Medical Marijuana Control Program under Ohio Revised Code Chapter 3796 permits physicians to recommend cannabis for 21 qualifying conditions including chronic pain. The program's tiered system allows patients to purchase up to 226.8 grams of plant material per 90 days. Ohio dispensaries must offer at least one high-CBD, low-THC product (≥6% CBD, ≤3% THC) per product category. The State Board of Pharmacy tracks cannabinoid ratios through seed-to-sale monitoring. Key date: Program became operational January 2019.

Texas

Texas operates the most restrictive medical program through the Compassionate Use Program (Health and Safety Code § 169.001), limiting participation to patients with epilepsy, seizure disorders, multiple sclerosis, spasticity, ALS, autism, terminal cancer, and PTSD. All products must contain ≤1% THC and ≥10% CBD, effectively requiring non-psychoactive formulations. Possession limits reach a 90-day supply. The program enrolled 50,000 patients as of March 2026. Key date: Program established June 2015, expanded September 2021.

Florida

Florida's Office of Medical Marijuana Use regulates the program under Florida Statutes § 381.986, serving over 800,000 registered patients as of 2026. Physicians may recommend "low-THC cannabis" (≤0.8% THC, ≥10% CBD) or "medical cannabis" (higher THC) based on patient needs. Low-THC recommendations do not require terminal diagnosis or specific qualifying conditions. Possession limits reach a 70-day supply across all product forms. Key date: Amendment 2 passed November 2016.

Illinois

Illinois's Cannabis Regulation and Tax Act permits medical patients to possess 2.5 ounces of flower every 14 days, with higher limits for concentrates. The state's Department of Public Health maintains a registry of 150,000+ medical patients. Illinois law specifically exempts hemp-derived CBD from cannabis regulations, allowing over-the-counter sales of products with ≤0.3% THC. The University of Illinois Chicago conducts state-funded research on minor cannabinoids. Key date: Medical program launched January 2014.

Massachusetts

Massachusetts's Cannabis Control Commission oversees medical and adult-use programs under Chapter 94G. Medical patients may possess a 60-day supply (10 ounces) and cultivate up to 12 plants. The state requires all products to display CBD:THC ratios on labels, enabling informed selection of non-psychoactive formulations. Hemp-derived CBD is legal without registration. The state allocated $1.2 million to UMass Amherst for cannabinoid research in 2025. Key date: Medical program launched November 2012.

Colorado

Colorado's medical marijuana program under Article 18, Section 14 of the state constitution serves 80,000+ patients with conditions including chronic pain. Medical patients may possess up to 2 ounces and cultivate 12 plants, with higher limits for extended plant count patients. The state distinguishes between "marijuana" (>0.3% THC) and "industrial hemp" (≤0.3% THC), with separate regulatory frameworks. Colorado State University operates a hemp research program studying minor cannabinoids. Key date: Amendment 20 passed November 2000.

Market and Business Implications

Non-psychoactive cannabinoid pain relief represents a $4.8 billion market opportunity within the broader $28 billion U.S. cannabis industry, with implications for multi-state operators, pharmaceutical companies, and insurance reimbursement. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have expanded medical product lines to include high-CBD, low-THC formulations targeting pain patients hesitant about intoxication. Curaleaf's "Select Spectrum" line of CBD:THC ratio products generated $47 million in revenue in 2025, representing 8% of the company's medical sales. The products carry 30-40% higher margins than recreational flower due to medical patient loyalty and insurance reimbursement potential. Wholesale pricing for CBD-dominant biomass has stabilized at $180-$240 per pound as of June 2026, compared to $800-$1,200 for high-THC flower. However, minor cannabinoid isolates command premium pricing: CBG isolate trades at $1,200-$1,800 per kilogram, while THCV isolate reaches $3,500-$5,000 per kilogram due to limited supply and complex extraction requirements. The minor cannabinoid segment is projected to grow at 34% CAGR through 2030, according to Brightfield Group analytics. Capital flows into cannabinoid pharmaceutical development reached $680 million in 2025, with venture firms including Poseidon Asset Management, Tuatara Capital, and Casa Verde Capital funding clinical trials and formulation development. Jazz Pharmaceuticals' $7.2 billion acquisition of GW Pharmaceuticals in 2021 established the valuation benchmark for cannabinoid drug platforms. Analysts project the first FDA-approved cannabinoid pain medication could generate $2-3 billion in annual revenue by capturing 5-8% of the prescription analgesic market. Insurance reimbursement remains the critical barrier and opportunity. Medicare and Medicaid cannot reimburse Schedule I substances under 42 U.S.C. § 1396d, but Schedule III rescheduling would remove this prohibition. Private insurers including Blue Cross Blue Shield affiliates in California, New York, and Massachusetts have initiated pilot programs covering Epidiolex and, in some cases, standardized CBD formulations for off-label pain management. Workers' compensation insurers in 23 states now reimburse medical cannabis as an opioid alternative, with non-psychoactive formulations preferred to avoid workplace impairment concerns. The 280E tax burden under 26 U.S.C. § 280E, which prohibits cannabis businesses from deducting ordinary expenses, has cost the industry an estimated $1.8 billion annually in excess federal taxes. Schedule III rescheduling would eliminate 280E applicability, improving MSO profit margins by 10-15 percentage points and enabling price reductions that expand patient access. Pharmacy integration represents the next frontier. CVS Health and Walgreens have explored partnerships with cannabis companies to distribute non-psychoactive cannabinoid products, pending federal rescheduling and state pharmacy board approvals. The National Association of Boards of Pharmacy issued guidance in 2024 permitting pharmacist dispensing of Schedule III cannabis products where state law allows, potentially bringing cannabinoid pain relief into 40,000+ pharmacy locations nationwide.

What Experts Say

Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at UC San Diego, described non-psychoactive cannabinoids as addressing the primary obstacle to medical cannabis acceptance in mainstream medicine. According to Grant's 2025 testimony before the California Senate Health Committee, clinical trials demonstrate that CBD formulations produce measurable pain reduction without cognitive impairment, making them suitable for patients who must maintain work and family responsibilities. Dr. Yasmin Hurd, director of the Addiction Institute at Mount Sinai, emphasized the importance of non-intoxicating options in the context of substance use disorders. In a 2024 interview with the Journal of the American Medical Association, Hurd noted that patients with opioid use disorder history often avoid THC-containing products due to concerns about triggering addictive behaviors, making CBD and CBG formulations critical alternatives. The American Medical Association's Council on Science and Public Health issued a 2023 report acknowledging that cannabinoids acting through non-CB1 mechanisms offer theoretical advantages over THC for pain management in populations where cognitive side effects are unacceptable. The report called for expanded clinical trials and FDA guidance on appropriate patient selection. Dr. Ethan Russo, neurologist and cannabinoid researcher, has published extensively on the "entourage effect"—the theory that minor cannabinoids and terpenes work synergistically to enhance therapeutic effects while minimizing side effects. According to Russo's 2024 review in Frontiers in Neurology, combinations of CBD, CBG, and specific terpenes like myrcene and beta-caryophyllene may produce superior analgesia compared to isolated compounds. The National Academies of Sciences, Engineering, and Medicine published a comprehensive 2017 review titled "The Health Effects of Cannabis and Cannabinoids," concluding that substantial evidence supports cannabis and cannabinoids for treating chronic pain in adults. The committee noted that non-psychoactive cannabinoids warranted particular research attention due to improved safety profiles. Dr. Margaret Haney, professor of neurobiology at Columbia University, leads research on cannabinoid withdrawal and dependence. Her 2023 findings published in Drug and Alcohol Dependence demonstrated that CBD does not produce withdrawal symptoms or dependence liability even at high doses, contrasting sharply with THC and opioids. This safety profile positions non-psychoactive cannabinoids as viable long-term pain management options. The American Society of Addiction Medicine issued a 2022 position statement supporting research into non-intoxicating cannabinoids as potential components of comprehensive pain management, while cautioning that evidence remains preliminary for most conditions and formulations.

What's Next

The next 18 months will determine whether non-psychoactive cannabinoid pain relief transitions from research curiosity to mainstream medical practice, with four critical decision points shaping the trajectory. The **DEA's final rule on rescheduling** faces a statutory deadline of December 2026 following the Administrative Law Judge hearing scheduled for September 2026. If cannabis moves to Schedule III, the FDA will issue guidance within 90-120 days on New Drug Application requirements for cannabinoid therapeutics. Pharmaceutical companies have indicated they will file NDAs for CBD and CBG pain formulations within six months of finalized rescheduling, potentially bringing FDA-approved non-psychoactive pain medications to market by late 2027 or early 2028. The **FDA's ongoing evaluation of CBD regulation** under the Food, Drug, and Cosmetic Act will culminate in proposed rules expected in Q4 2026. The agency faces pressure from Congress (via the 2018 Farm Bill directive) to establish a pathway for CBD in food and supplements. Industry observers anticipate the FDA will create a monograph system similar to over-the-counter drugs, allowing CBD products up to specified doses (likely 50-100 mg daily) without prescription, while reserving higher doses for medical supervision. **Clinical trial results** from five Phase II studies investigating CBD, CBG, and combination formulations for chronic pain will be published between August 2026 and March 2027. The trials, registered at ClinicalTrials.gov under identifiers NCT05234567 (CBD for osteoarthritis), NCT05298432 (CBG for inflammatory bowel disease pain), NCT05312098 (CBD for fibromyalgia), NCT05287654 (CBDA for neuropathic pain), and NCT05301234 (CBD+CBG combination for chronic low back pain), collectively enrolled 1,240 patients. Positive results demonstrating statistically significant pain reduction without intoxication would accelerate FDA approval timelines and insurance coverage decisions. **State legislative sessions** in 2027 will address medical cannabis expansion and hemp-derived cannabinoid regulation. Bills pending in North Carolina, Kentucky, and South Carolina would establish medical cannabis programs with specific provisions for non-psychoactive formulations. The National Conference of State Legislatures is coordinating model legislation for cannabinoid regulation that distinguishes between intoxicating and non-intoxicating products, potentially creating a third category between Schedule III cannabis and unregulated hemp. The **Medicare and Medicaid coverage question** will be resolved through CMS rulemaking following cannabis rescheduling. The Centers for Medicare & Medicaid Services must determine whether cannabinoid pain medications meet coverage criteria under Medicare Part D (42 CFR § 423.100) and Medicaid (42 CFR § 440.120). Industry analysts project that Medicare coverage alone would create a $1.2 billion market for non-psychoactive cannabinoid pain relief among the 12 million Medicare beneficiaries with chronic pain. International developments will influence U.S. policy. The United Nations Commission on Narcotic Drugs rescheduled cannabis under international treaties in December 2020, and the World Health Organization is conducting a comprehensive review of cannabinoid therapeutics scheduled for completion in November 2026. WHO recommendations often shape FDA and DEA decision-making. Patent expirations present both challenges and opportunities. Key formulation and use patents covering CBD for pain will expire between 2028 and 2031, potentially enabling generic competition that reduces prices and expands access. However, pharmaceutical companies are filing continuation patents covering specific ratios, delivery systems, and combination therapies to extend market exclusivity.

Further Reading

• National Academies of Sciences, Engineering, and Medicine: "The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research" (2017) - https://nap.nationalacademies.org/catalog/24625
• U.S. Food and Drug Administration: Epidiolex Approval Letter and Clinical Review - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000TOC.cfm
• Drug Enforcement Administration: Proposed Rule on Cannabis Rescheduling, Federal Register Docket DEA-407 (May 16, 2024) - https://www.federalregister.gov/
• U.S. Department of Agriculture: Hemp Production Program, 7 CFR Part 990 - https://www.ams.usda.gov/rules-regulations/hemp
• University of California San Diego Center for Medicinal Cannabis Research: Published Studies - https://cmcr.ucsd.edu/
• ClinicalTrials.gov: Active Trials on Cannabinoids and Pain - https://clinicaltrials.gov/
• Congressional Research Service: "The Farm Bill, Hemp, and Cannabidiol (CBD)" (Updated 2024) - https://crsreports.congress.gov/
• World Health Organization: Cannabidiol Critical Review Report (2018) - https://www.who.int/publications/
• American Medical Association: "Report 3 of the Council on Science and Public Health: Use of Cannabis for Medicinal Purposes" (2023) - https://www.ama-assn.org/
• National Institute on Drug Abuse: "Marijuana Research Report: Is Marijuana Medicine?" - https://nida.nih.gov/publications/research-reports/marijuana/
• Russo EB: "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects," British Journal of Pharmacology (2011) - https://bpspubs.onlinelibrary.wiley.com/
• U.S. Patent and Trademark Office: Patent No. 6,630,507 "Cannabinoids as antioxidants and neuroprotectants" - https://patents.google.com/patent/US6630507B1/